Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $1.09 in the prior trading day, Pyxis Oncology Inc (NASDAQ: PYXS) closed at $1.11, up 1.83%. In other words, the price has increased by $1.83 from its previous closing price. On the day, 1.42 million shares were traded. PYXS stock price reached its highest trading level at $1.16 during the session, while it also had its lowest trading level at $1.08.
Ratios:
Our goal is to gain a better understanding of PYXS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.29 and its Current Ratio is at 4.29. In the meantime, Its Debt-to-Equity ratio is 0.28 whereas as Long-Term Debt/Eq ratio is at 0.25.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 21 ’25 when HUMPHREY RACHEL bought 13,896 shares for $1.03 per share.
HUMPHREY RACHEL bought 200 shares of PYXS for $194 on Apr 17 ’25. On Apr 14 ’25, another insider, HUMPHREY RACHEL, who serves as the Director of the company, bought 1,400 shares for $0.97 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PYXS now has a Market Capitalization of 69113280 and an Enterprise Value of 11930279. For the stock, the TTM Price-to-Sale (P/S) ratio is 24.51 while its Price-to-Book (P/B) ratio in mrq is 1.00. Its current Enterprise Value per Revenue stands at 4.231 whereas that against EBITDA is -0.148.
Stock Price History:
The Beta on a monthly basis for PYXS is 1.38, which has changed by -0.3018868 over the last 52 weeks, in comparison to a change of 0.16098404 over the same period for the S&P500. Over the past 52 weeks, PYXS has reached a high of $5.55, while it has fallen to a 52-week low of $0.83. The 50-Day Moving Average of the stock is -71.12%, while the 200-Day Moving Average is calculated to be -44.33%.
Shares Statistics:
The stock has traded on average 1.04M shares per day over the past 3-months and 2568930 shares per day over the last 10 days, according to various share statistics. A total of 62.15M shares are outstanding, with a floating share count of 48.09M. Insiders hold about 22.76% of the company’s shares, while institutions hold 38.03% stake in the company. Shares short for PYXS as of 1765756800 were 1933041 with a Short Ratio of 1.86, compared to 1763078400 on 4541093. Therefore, it implies a Short% of Shares Outstanding of 1933041 and a Short% of Float of 3.75.
Earnings Estimates
The market rating of Pyxis Oncology Inc (PYXS) is currently shaped by the ongoing analysis conducted by 9.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.23 and low estimates of -$0.39.
Analysts are recommending an EPS of between -$1.14 and -$1.38 for the fiscal current year, implying an average EPS of -$1.3. EPS for the following year is -$1.18, with 8.0 analysts recommending between -$0.79 and -$1.54.
